Press enter or spacebar to select a desired language.
Electronic Library of Medicine - Jordan

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Article Date
August 24, 2020

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Authors: Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., ... & Pruijssers, A. J.

Published: July 14, 2020


The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein.


We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 μg, 100 μg, or 250 μg. There were 15 participants in each dose group.

To continue reading the full article please follow the link:

 PDF version: